BC
COGT icon

Bridgefront Capital’s Cogent Biosciences COGT Stock Holding History

Bridgefront Capital’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$308K Buy
+7,957
New +$278K 0.08% 374
2026
Q1 		– Sell
-14,186
Closed -$504K – 560
2025
Q4 		$504K Buy
+14,186
New +$399K 0.13% 271

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bridgefront Capital's COGT Position: Q2 2026 in Review

Bridgefront Capital opened a new position in Cogent Biosciences (COGT) in Q2 2026: 7,957 shares worth $308K. The stake represents 0.08% of the portfolio and ranks #374 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in COGT as recently as Q4 2025.

Bridgefront Capital first reported a position in COGT in Q4 2025 and has held it in 2 quarters since. The position peaked at $504K in Q4 2025. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Bridgefront Capital held 7,957 shares of Cogent Biosciences worth $308K as of Q2 2026.
  • Cogent Biosciences was a new Bridgefront Capital position in Q2 2026.
  • Cogent Biosciences made up 0.08% of Bridgefront Capital's portfolio in Q2 2026, its #374 holding.
  • Bridgefront Capital first reported a position in Cogent Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Bridgefront Capital's Cogent Biosciences position peaked at $504K in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.